| Literature DB >> 35873799 |
Arshiya Sultana1, Khaleequr Rahman2, Md Belal Bin Heyat3, Faijan Akhtar4, Abdullah Y Muaad5.
Abstract
Premenstrual syndrome (PMS) significantly lowers the quality of life and impairs personal and social relationships in reproductive-age women. Some recommendations are that inappropriate oxidative stress and inflammatory response are involved in PMS. Various nutritional supplements and herbs showed neuro-psycho-pharmacological activity with antioxidant and anti-inflammatory properties. This study aims to determine the systematic review of randomized controlled trials (RCTs) of herbal medicine and nutritional supplements in PMS. We also comprehensively highlighted the role of oxidative stress, inflammation, and mitochondrial changes on PMS with the application of computational intelligence. We used PRISMA and research question-based techniques to collect the data for evaluation of our study on different databases such as Scopus, PubMed, and PROSPERO from 1990 to 2022. The methodological quality of the published study was assessed by the modified Jadad scale. In addition, we used network visualization and word cloud techniques to find the closest terms of the study based on previous publications. While we also used computational intelligence techniques to give the idea for the classification of experimental data from PMS. We found 25 randomized controlled studies with 1949 participants (mean ± SD: 77.96 ± 22.753) using the PRISMA technique, and all were high-quality studies. We also extracted the closest terms related to our study using network visualization techniques. This work has revealed the future direction and research gap on the role of oxidative stress and inflammation in PMS. In vitro and in vivo studies showed that bioactive molecules such as curcumin, allicin, anethole, thymoquinone, cyanidin 3-glucoside, gamma-linoleic acid, and various molecules not only have antioxidant and anti-inflammatory properties but also other various activities such as GABA-A receptor agonist, serotonergic, antidepressant, sedative, and analgesic. Traditional Unani Herbal medicine and nutritional supplements can effectively relieve PMS symptoms as they possess many bioactive molecules that are pharmacologically proven for the aforementioned properties. Hence, these biomolecules might influence a complex physical and psychological disease process like PMS. However, more rigorous research studies are recommended for in-depth knowledge of the efficacy of bioactive molecules on premenstrual syndrome in clinical trials.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35873799 PMCID: PMC9300296 DOI: 10.1155/2022/3599246
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Various inclusion and exclusion criteria.
| Criteria | Inclusion | Exclusion | Justification |
|---|---|---|---|
| Subject | Patients with premenstrual symptoms | No exclusion | Included all PMSS scales |
| Language | English and Persian | Other languages | Probabilities of misapprehension of data in other languages may therefore disturb the accuracy |
| Access | Can access full text | Cannot access full text | To confirm the explanation of an article more precisely |
| Methodology | All | No exclusions | All methodologies were included for a holistic view |
| Nature of the article | Research and Survey | Observational studies, review, book, and editorial | Review articles comprehending a generalized discussion over a topic would not sufficiently answer our specific research question |
Figure 1PRISMA of the proposed study.
Figure 2Publisher-wise previously published articles related to RCTs on PMS and herbal medicine.
Figure 3Country-wise previously published articles related to RCTs on PMS and herbal medicine.
Figure 4Year-wise publications related to RCTs on PMS and herbal medicine.
The characteristics of the published RCTs on herbal medicines and nutritional supplements and their bioactive molecules with pharmacological activities.
| Blinding in RCT | Part. | Age (years) | Tools | Exp. group | Cont. Group | Duration of Rx | Result | Adv. Event | Bioactive molecules | Pharm. Actions | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Triple-blind | 76 | 18-24 | PSST, | One capsule (500 mg of curcuminoid+5 mg piperine) (n =38) | Placebo ( | Daily for 7days before until 3days after menstruation for 3 menstrual cycles | Curcumin significantly increased the median serum levels of vitamin D, liver function enzyme test, but did not affect blood glucose | Not reported | Curcumin | Antioxidant, anti-inflammatory, antimicrobial and anticarcinogenic | [ |
| Double-blind | 129 | 15-49 | PSST | 400 mg (1.1 mg allicin) ( | Placebo ( | One tablet daily for 3 cycles | Significant reduction in the symptoms | Reported | Allicin, inhibits MAO enzyme, acts as an antidepressant | Anti-depressant, anti-inflammatory antioxidant, immunomodulator | [ |
| Double-blind | 84 | 18-35 | PSST | 110 mg capsules of anise ( | Placebo (starch) ( | TID, 7 days before the start of the menstruation and first 3 days during menses for 2 consecutive menstruations | Decreased the symptoms in comparison to placebo | Reported | Anethole | Antioxidant, hypoglycemic, hypolipidemic, anticonvulsant selective moderator of estrogenic receptors | [ |
| Double-blind | 84 | 18-35 | DASS 21, COPE | Oral capsules containing 500 mg of | Placebo ( | Same as above | Significant reduction in overall severity of premenstrual syndrome in the intervention group | Not reported | Thymoquinone | Increase brain GABA, anti-anxiety, antioxidant, anti-inflammatory | [ |
| Double-blind | 84 | 20-35 | PSST | 450 mg capsules of flowers of | Placebo ( | TID from the 21st day to the 3rd day of their next cycle for 2 consecutive cycles | More effectively symptoms were improved in experimental group | Reported | Cyanidin 3-glucoside, (anthocyanin) | Anti-inflammatory, antioxidant, analgesic, anxiolytic, sedative and anticonvulsant | [ |
| Double-blind | 72 | >18 | DRSP | 80 mg B6 ( | EM | Four capsules BID from day 1 of menstruation of new cycle till 2 months | Both groups were effective in PMDD | Not reported | Omega fatty acid | Antioxidant | [ |
| Double-blind | 60 | 18-30 | 30-item questionnaire based on DSM-VI | 30-mg zinc gluconate | Placebo ( | 12 weeks | Significant reductions in symptoms and increase | Not reported | Increases in BDNF | Antidepressant, | [ |
| Single-blind | 60 | 18-45 | PMSS scale | 1000 mg of | Placebo ( | 2 capsules, BID from day 16 of the menstrual cycle to day 5 of the next cycle for 3 consecutive cycles | Significant decrease in symptoms and improvement in EQ-5D-5L index value in the experimental group | Reported | Polypodin A and polypodin B | Stress modulator, antidepressant, antioxidant, immunomodulator, analgesic, neuroprotective, anti-inflammatory, antioxidant properties, effects on the rennin-angiotensin system, and increase 5- hydroxytryptamine in the brain | [ |
| Double blind | 44 | 18-25 | BDI-S, BAI | Vitamin D3 (50,000 IU) ( | Placebo pearl ( | Every 15 days for 4 months | 25(OH)D, serum IL-12 and TAC levels improved significantly in the test group | Not reported | Antidepressant, | [ | |
| Single-blind | 101 | 20-50 | PMTS-O, VAS | Pollen pistil extract serelys | Placebo (n =51) | 4 months | Significant symptom reduction with serelys treatment | Not reported | Flavonoids, tannins and polyphenols | [ | |
| Single-blind | 60 | 18-45 | PMTS-O, PMTS-SR, VAS score | 666 mg of | Placebo ( | Orally, BID for the 15 days prior to the expected date of menses for 2 cycles | Significant reductions in the test group than the placebo | Not reported | Sesquiterpene jatamansone | Anti-depressant neuroprotective activity. | [ |
| Double blind | 70 | Premenopausal women | DSM-IV | Curcumin (100 mg) ( | Placebo (brown sugar) ( | 2 capsules BID daily for 7 days before and three days during menstruation for three successive cycles | Significant reduction in severity of PMS symptoms | Not reported | Curcumin | Antidepressant due to serotonergic system, anti-inflammatory, antioxidant, neuroprotective | [ |
| Double-blind | 100 | University students | GHQ-28, PSST |
| Placebo ( | Daily for three cycles from day 1 of last day of menstrual cycle | Significant reduction of somatic, psychological and social symptoms | Not reported | Triterpenoids (ursolic and oleanolic acids) accountable for the inhibition of rat brain GABA transaminase. | Anxiolytic, anti-depressant spasmolytic, sedative, antioxidant, immunomodulatory antiviral and antispasmodic | [ |
| Triple-blind | 100 | 20-45 | DSR, BDI | Wheat germ extract (400 mg capsules) | Placebo ( | TID a day between the 16th day of the menstrual cycle to the 5th day of the next menstrual period for two cycles | Significant reduction in symptoms | Not reported | Magnesium, zinc, calcium, antioxidants including beta-carotene (for vitamin A), thiamin, folic acid, vit E, C, B12, B6, riboflavin, niacin, iron, amino acids, and enzymes. Linoleic acid | Antioxidant, anti-inflammatory | [ |
| Double-blind | 70 | Students | DSM-IV | 100 mg/12 h. curcumin capsules ( | Placebo ( | 3 successive menstrual cycles and each cycle ran 10 days (in each menstrual cycle 7 days before and 3 days after onset of menstrual bleeding) | Significantly increase in BDNF levels and PMS symptoms were significantly reduced in the test than placebo group | Not reported | Curcumin | Modulating level of BDNF, anti-depressant | [ |
| Triple-blind | 80 | 18-30 | DSM IV-TR | 1500 mg primrose oil ( | Placebo ( | TID for three months | Reduction of symptom severity in both primrose and placebo group | Not reported | Linoleic acid and gamma linoleic acid | Antioxidant, anti-inflammatory | [ |
| Double-blind | 70 | 18-35 | DSM-IV | Two ginger capsules 250 mg ( | Placebo ( | BID (7days) before menstruation to three days after menstruation for three cycles | Reduction in symptoms | Reported | Sesquiterpenoids, with (-)-zingiberene. Sesquiterpene lactones (SLs) are responsible for their anti-inflammatory activity | Immuno-modulatory, anti-tumorigenic, anti-inflammatory, anti-apoptotic, anti-hyperglycemic, anti-lipidemic, and anti-emetic actions (Rehman et al. 2011) | [ |
| Single-blind | 60 | 13-40 | PMTS-SR, PMTS-O |
| Placebo ( | BID daily, 10 days before menstruation in every cycle for 3 cycles | A significant reduction in scores was observed in the test group than placebo ( | Not reported | Flavonoid | Anxiolytic, antioxidant, chemopreventive, immunomodulatory and cytotoxicity, antimicrobial, antifungal, antinociceptive, opioidergic, antiepileptic neuroprotective | [ |
| Double-blind | 128 | Child bearing age | DSR |
| Placebo ( | Orally in the morning from the 6th day prior menses until menstruation, for 6 consecutive cycles | Significant relief of mild and moderate PMS symptoms | Not reported | Flavonoid | Antioxidant, chemo preventive, immunomodulatory and cytotoxicity, antimicrobial, antifungal, antinociceptive, opioidergic, antiepileptic neuroprotective | [ |
| Double blind | 80 | 18-30 | DSM-IV | 10 drops of citrus essence ( | Placebo ( | TID during the luteal phase for two cycles | Reduction in the severity of premenstrual syndrome in the experimental group | Not reported |
| Enhancing mood and effects sedation, antispasmodic, anti-inflammatory, antioxidant (Hsouna 2017) | [ |
| Double blind | 60 | — | DRSP-Q | 30 drops of fennel extract ( | Placebo ( | Every 8 hours for 3 days during menses for three months | Significantly greater improvement with the fennel extract than placebo | Reported | Anethole, estragole | Prostaglandin inhibitor, antioxidant, anti-inflammatory, analgesic (Korinek et al., 2021) | [ |
| Double-blind | 36 | 18-45 | DSR |
| Placebo ( | BID for cycle 4-10 months | Significantly benefit on symptoms | Reported | Hypericin inhibits MAO enzyme and acts as an antidepressant | Neuroprotective, anti-depressant, antiangiogenic | [ |
| Single-blind | 90 | 18-30 | DSM-IV, BDI |
| Placebo ( | TID from the 16th day of the menstrual cycle to the 5th day of the next cycle for 2 cycles | Significant decrease in the overall severity of symptoms in the experiment group | Reported | Quercetin is an effective inhibitor of histamine release Bioflavonoids are stress modulator | Anti-inflammatory, anxiolytic, anti-depression | [ |
| Double blind | 50 | 20-45 | Premenstrual daily symptoms score | Capsule saffron 30 mg/day ( | Capsule placebo ( | 15 mg BID for a two menstrual cycles | Significant difference in the total PMS and HDRS scores | Reported | Crocin and safranal of saffron inhibit the reuptake of dopamine, norepinephrine and serotonin | Antioxidant, anti-depressant, | [ |
| Double blind | 101 | 20-50 | Steiner premenstrual tension syndrome and VAS | Femal, 160 mg ( | Placebo ( | BID for four menstrual cycles | Significant reduction in PSF and PMTS scale | Reported | Thymol, camphor | Serotonin reuptake inhibitors | [ |
Total participants: 1949 with mean ± SD: 77.96 ± 22.753, variance: 517.71; and CI: 4.55. BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory; BDI-SL, Beck Depression Short Inventory; COPE: calendar of premenstrual experience; DSR: daily symptom report; DRSP-Q: daily record of severity of problem questionnaire; daily premenstrual syndrome questionnaire with DSM-IV; HDRS: Hamilton Depression Rating Scale: PMTS-O: Steiner premenstrual tension observer questionnaire; PMTS-SR: Steiner premenstrual tension self-rating questionnaire; PSST: Premenstrual Symptoms Screening Tool questionnaire; SD: standard deviation; CI: confidence interval.
Randomized controlled studies showing risk of bias.
| Study | Randomization | Approach of randomization appropriate | Blinding | Approach of blinding appropriate | Presentation of withdrawals and dropouts | Presentation of the inclusion/exclusion criteria | Adverse effects | Statistical | Modified |
|---|---|---|---|---|---|---|---|---|---|
| Ozgoli et al., 2009 [ | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 7.5 |
| Heidari et al., 2019 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Arabnezhad et al., 2022 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Jafari et al., 2021 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Farahmand et al., 2020 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Maskani et al., 2020 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Farahmand et al. 2020 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Brown et al., 2020 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Jafari et al., 2020 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Khanam and Sultana, 2020 [ | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 7.5 |
| Winther et al., 2018 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Malik et al., 2018 [ | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 6.5 |
| Khayat et al., 2015 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Akbarzadeh et al., 2015 [ | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 5 |
| Ataollahi et al. 2015 [ | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 5 |
| Fanaei et al., 2016 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Saki et al., 2015 [ | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 5 |
| Khayat et al., 2014 [ | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 7 |
| Shameem et al., 2014 [ | 1 | 1 | 0.5 | 1 | 0 | 1 | 0 | 1 | 5.5 |
| Zamani et al., 2012 [ | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 |
| Ozgoli et al., 2011 [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| Delaram et al., 2011 [ | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| Canning et al., 2010 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Hosseini et al., 2008 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Gerhardsen et al., 2008 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
Figure 5Quality assessment of randomized controlled trials.
Figure 6Potential mechanisms of inflammation and oxidative stress in PMS. Antioxidant and anti-inflammatory effects of nutritional supplements and herbal medicines.
Figure 7Antioxidant and anti-inflammatory effects of phytoconstituents in herbal medicine and nutritional supplements.
Figure 8Heat map of the experimental and placebo group of the PMS. It showed the relation between premenstrual scale score, health-related quality of life index value related to the premenstrual psychosomatic and its behavioral symptoms of baseline (BL), three cycles with treatments, and one follow-up (FU) without treatment.
Performance of the system is based on control and Polypody classification using computational intelligence techniques such as SVM-RBF and RF classifiers.
| Classifier | Model | Accuracy (%) | Recall (%) | Specificity (%) | Precision (%) | AUC (%) |
|---|---|---|---|---|---|---|
| SVM-RBF | Leave one out | 88.30 | 88.30 | 88.30 | 88.40 | 91.30 |
| RF |
|
|
|
| 89.10 | |
| SVM-RBF | CV-5 | 86.70 | 86.70 | 86.70 | 86.70 | 91.60 |
| RF | 88.30 | 88.30 | 88.30 | 88.40 | 89.30 | |
| Mean | 88.325 | 88.325 | 88.425 | 90.325 | 88.325 | |
| ±Standard deviation | 1.166 | 1.166 | 1.237 | 1.132 | 1.166 | |
| Variance | 1.361 | 1.361 | 1.531 | 1.281 | 1.361 | |
Figure 9Closest terms of the present study based on (a) word cloud and (b) network visualization.
Description of the proposed research questions based on closest terms using the network visualization model.
| S. No. | Research questions | Closest terms |
|---|---|---|
| 1. | What is etiopathogenesis and the role of oxidative stress, inflammation leading to mitochondrial changes in premenstrual psychosomatic, and its behavioral symptoms? | Anxiety, depression, disorder, menstrual cycle, pain, patient, placebo, PMS, premenstrual symptoms, premenstrual syndrome, relationship, role, severity, symptom, behavioral, and woman |
| 2. | What are the various mechanisms of action in nutritional supplements and herbal medicines with their phytochemical constituents in premenstrual psychosomatic and its behavioral symptoms? | Anxiety, antioxidants, biomarkers, calcium, clinical trials, depression, inflammation, infection, menstrual cycle, patients, premenstrual syndrome, roots, superoxide, symptom, woman, BDR, brain, herbal medicine, nutrition, phytochemicals, symptom, PMS, protein, ROS, and woman |
| 3. | Does computational intelligence have a role in PMS data analysis for future modulation of premenstrual symptoms? | AI, analysis, data, classification, classifier, recognition, computational intelligence, machine learning, PMS, prediction, RF, and SVM |